Cellarity Platform
Multi-omics AI-powered platform for cell state-correcting drug discovery
Platform · OtherCompany source
Company profile
About Cellarity
Cellarity is a biotechnology company pioneering a novel approach to drug discovery by developing Cell State-Correcting therapeutics. The company addresses the limitations of traditional drug discovery, which is often constrained by human bias and unable to comprehensively map the complex cellular interactions that characterize disease cascades. Cellarity's proprietary multi-omics AI-powered platform reveals new biological pathways and enables the regulation of genetic switches to restore proper cell function. This innovative approach allows the company to develop game-changing therapeutics for a range of complex diseases. Their lead program, CLY-124, targets sickle cell disease. By focusing on correcting dynamic cell states rather than single targets, Cellarity aims to address diseases that have been difficult to treat with conventional methods. The company's platform integrates advanced AI and machine learning with comprehensive biological data to identify novel therapeutic interventions.
Company description Cellarity official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Work at Cellarity?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Complex diseases
- Sickle Cell Disease
Who it serves
- Pharma
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
Company milestones
Platform expansion
Development of lead program CLY-124 for sickle cell disease
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
CLY-124
Cell state-correcting therapeutic for sickle cell disease
Other · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans.Science translational medicine · Jul 22, 2026
Active learning framework leveraging transcriptomics identifies modulators of disease phenotypes.Science (New York, N.Y.) · Nov 27, 2025
A large-scale human toxicogenomics resource for drug-induced liver injury prediction.Nature communications · Nov 13, 2025
AAnet Resolves a Continuum of Spatially Localized Cell States to Unveil Intratumoral Heterogeneity.Cancer discovery · Oct 6, 2025
Defining breast epithelial cell types in the single-cell era.Developmental cell · Sep 8, 2025
Defining and benchmarking open problems in single-cell analysis.Nature biotechnology · Jul 1, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Cell state correction
Restoring proper cell function through regulation of genetic switches
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Cellarity
Recent articles published on Cellarity's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.